The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma
(1) Background: Chemokines and chemokine receptors play an important role in tumor development. The aim of this study was to check the significance of <i>CCL5</i> and <i>CCR1</i> variants with response rate, survival, and the level of regulated on activation, normal T cells e...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/6/2384 |
| _version_ | 1797610930791514112 |
|---|---|
| author | Sylwia Popek-Marciniec Wojciech Styk Magdalena Wojcierowska-Litwin Aneta Szudy-Szczyrek Paul Dudek Grazyna Swiderska-Kolacz Joanna Czerwik-Marcinkowska Szymon Zmorzynski |
| author_facet | Sylwia Popek-Marciniec Wojciech Styk Magdalena Wojcierowska-Litwin Aneta Szudy-Szczyrek Paul Dudek Grazyna Swiderska-Kolacz Joanna Czerwik-Marcinkowska Szymon Zmorzynski |
| author_sort | Sylwia Popek-Marciniec |
| collection | DOAJ |
| description | (1) Background: Chemokines and chemokine receptors play an important role in tumor development. The aim of this study was to check the significance of <i>CCL5</i> and <i>CCR1</i> variants with response rate, survival, and the level of regulated on activation, normal T cells expressed and secreted (RANTES/CCL5) in multiple myeloma (MM) patients; (2) Methods: Genomic DNA from 101 newly diagnosed MM patients and 100 healthy blood donors were analyzed by Real-time PCR method (for <i>CCL5</i> and <i>CCR1</i> genotyping). In a subgroup of 70 MM patients, serum samples were collected to determine the level of RANTES; (3) Results: multivariate Cox regression showed increased risk of disease relapse or progression (HR = 4.77; <i>p</i> = 0.01) in MM patients with CG + CC genotypes of <i>CCL5</i> rs2280788. In contrast, CT + TT genotypes of <i>CCL5</i> rs2107538 were associated withdecreased risk of death (HR = 0.18; <i>p</i> = 0.028) and disease relapse or progression (HR = 0.26; <i>p</i> = 0.01). In MM patients with major genotypes of rs2280789, rs2280788, and rs2107538, higher survival rates were observed in response to treatment with thalidomide and bortezomib. Statistically significant lower RANTES levels were seen in minor genotypes and heterozygotes of <i>CCL5</i> and <i>CCR1</i> variants; (4) Conclusions: Major genotypes of <i>CCL5</i> variants may be independent positive prognostic factors in MM. |
| first_indexed | 2024-03-11T06:21:50Z |
| format | Article |
| id | doaj.art-22200594fa9e476fa12bd0ea19d82fab |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T06:21:50Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-22200594fa9e476fa12bd0ea19d82fab2023-11-17T11:52:08ZengMDPI AGJournal of Clinical Medicine2077-03832023-03-01126238410.3390/jcm12062384The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple MyelomaSylwia Popek-Marciniec0Wojciech Styk1Magdalena Wojcierowska-Litwin2Aneta Szudy-Szczyrek3Paul Dudek4Grazyna Swiderska-Kolacz5Joanna Czerwik-Marcinkowska6Szymon Zmorzynski7Department of Cancer Genetics with Cytogenetic Laboratory, Medical University of Lublin, 20-059 Lublin, PolandDepartment of Psychology, Medical University of Lublin, 20-059 Lublin, PolandDepartment of Cancer Genetics with Cytogenetic Laboratory, Medical University of Lublin, 20-059 Lublin, PolandChair and Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-059 Lublin, PolandDepartment of Cancer Genetics with Cytogenetic Laboratory, Medical University of Lublin, 20-059 Lublin, PolandInstitute of Biology, Jan Kochanowski University, 25-406 Kielce, PolandInstitute of Biology, Jan Kochanowski University, 25-406 Kielce, PolandDepartment of Cancer Genetics with Cytogenetic Laboratory, Medical University of Lublin, 20-059 Lublin, Poland(1) Background: Chemokines and chemokine receptors play an important role in tumor development. The aim of this study was to check the significance of <i>CCL5</i> and <i>CCR1</i> variants with response rate, survival, and the level of regulated on activation, normal T cells expressed and secreted (RANTES/CCL5) in multiple myeloma (MM) patients; (2) Methods: Genomic DNA from 101 newly diagnosed MM patients and 100 healthy blood donors were analyzed by Real-time PCR method (for <i>CCL5</i> and <i>CCR1</i> genotyping). In a subgroup of 70 MM patients, serum samples were collected to determine the level of RANTES; (3) Results: multivariate Cox regression showed increased risk of disease relapse or progression (HR = 4.77; <i>p</i> = 0.01) in MM patients with CG + CC genotypes of <i>CCL5</i> rs2280788. In contrast, CT + TT genotypes of <i>CCL5</i> rs2107538 were associated withdecreased risk of death (HR = 0.18; <i>p</i> = 0.028) and disease relapse or progression (HR = 0.26; <i>p</i> = 0.01). In MM patients with major genotypes of rs2280789, rs2280788, and rs2107538, higher survival rates were observed in response to treatment with thalidomide and bortezomib. Statistically significant lower RANTES levels were seen in minor genotypes and heterozygotes of <i>CCL5</i> and <i>CCR1</i> variants; (4) Conclusions: Major genotypes of <i>CCL5</i> variants may be independent positive prognostic factors in MM.https://www.mdpi.com/2077-0383/12/6/2384<i>CCL5</i> gene<i>CCR1</i> genechemokine receptorschemokinesgenetic variantsmultiple myeloma |
| spellingShingle | Sylwia Popek-Marciniec Wojciech Styk Magdalena Wojcierowska-Litwin Aneta Szudy-Szczyrek Paul Dudek Grazyna Swiderska-Kolacz Joanna Czerwik-Marcinkowska Szymon Zmorzynski The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma Journal of Clinical Medicine <i>CCL5</i> gene <i>CCR1</i> gene chemokine receptors chemokines genetic variants multiple myeloma |
| title | The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma |
| title_full | The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma |
| title_fullStr | The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma |
| title_full_unstemmed | The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma |
| title_short | The Relationship of <i>CCL5</i> and <i>CCR1</i> Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma |
| title_sort | relationship of i ccl5 i and i ccr1 i variants with response rate and survival taking into account thalidomide bortezomib treatment in patients with multiple myeloma |
| topic | <i>CCL5</i> gene <i>CCR1</i> gene chemokine receptors chemokines genetic variants multiple myeloma |
| url | https://www.mdpi.com/2077-0383/12/6/2384 |
| work_keys_str_mv | AT sylwiapopekmarciniec therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT wojciechstyk therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT magdalenawojcierowskalitwin therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT anetaszudyszczyrek therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT pauldudek therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT grazynaswiderskakolacz therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT joannaczerwikmarcinkowska therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT szymonzmorzynski therelationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT sylwiapopekmarciniec relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT wojciechstyk relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT magdalenawojcierowskalitwin relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT anetaszudyszczyrek relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT pauldudek relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT grazynaswiderskakolacz relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT joannaczerwikmarcinkowska relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma AT szymonzmorzynski relationshipoficcl5iandiccr1ivariantswithresponserateandsurvivaltakingintoaccountthalidomidebortezomibtreatmentinpatientswithmultiplemyeloma |